Market closed

Insmed/$INSM

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About Insmed

Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.

Ticker

$INSM

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Bridgewater, United States

Employees

912

Website

www.insmed.com

Insmed Metrics

BasicAdvanced

$12B

-

-$5.56

1.11 -

Price and volume

Market cap

$12B

Beta

1.11

52-week high

$80.53

52-week low

$21.92

Average daily volume

1.8M

Financial strength

Current ratio

6.365

Quick ratio

5.827

Long term debt to equity

237.769

Total debt to equity

239.942

Interest coverage (TTM)

-8.45%

Management effectiveness

Return on assets (TTM)

-26.05%

Return on equity (TTM)

-890.75%

Valuation

Price to revenue (TTM)

31.248

Price to book

25.5

Price to tangible book (TTM)

42.9

Price to free cash flow (TTM)

-16.85

Growth

Revenue change (TTM)

22.13%

Earnings per share change (TTM)

5.62%

3-year revenue growth (CAGR)

25.44%

3-year earnings per share growth (CAGR)

12.37%

What the Analysts think about Insmed

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Insmed stock.

Insmed Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

Insmed Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Insmed News

AllArticlesVideos

Insmed: PAH Treatment Advancement With 2nd Half 2025 Top-Line Data

Seeking Alpha·2 months ago

Insmed Incorporated (INSM) Q3 2024 Earnings Call Transcript

Seeking Alpha·2 months ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $INSM

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Insmed stock?

Insmed (INSM) has a market cap of $12B as of January 15, 2025.

What is the P/E ratio for Insmed stock?

The price to earnings (P/E) ratio for Insmed (INSM) stock is 0 as of January 15, 2025.

Does Insmed stock pay dividends?

No, Insmed (INSM) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Insmed dividend payment date?

Insmed (INSM) stock does not pay dividends to its shareholders.

What is the beta indicator for Insmed?

Insmed (INSM) has a beta rating of 1.11. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.